Our Strategy

Through our clinical trials program, we aim to develop and validate a variety of analytical tools.

By employing these tools in different research settings, we hope to understand the mechanism and natural history of disease, as we strive to develop and test new  biomarkers and therapies.

Clinical trials involve several key components

Generating a hypothesis

Clinical trials exist in order to test a hypothesis. This is driven by a set of key research questions that are yet to be answered.

Optimising the study protocol

Deciding upon a suitable and practical study design is an important process. It acts as a guide for all researchers involved in the study. There needs to be careful consideration regarding patient recruitment and the study timeline.

Recruiting patients

After ethical approval, patients can be screened for the study eligibility criteria. Patients are fully informed about the study protocol, before formal consent is obtained.

Collecting data

Data are collected and stored according to the study protocol. A unique study ID for each patient ensures anonymisation of patients.

Performing the analysis

The analytical methods must be validated to ensure accuracy and consistency. Statistical tests are applied to help interpret the findings.

Publicising the results

Just as important as the study itself is how the results are publicised. This includes publication in appropriate medical journals and presentation at international conferences as well as informing patients and the wider public.

Our current clinical trials

We have several studies that are currently active. The core study collected data every two months for a whole year. The daytime variability study assessed each patient on three occasions throughout a single day (9am, 12pm and 3pm). The ultrasound and EMG study combined these two non-invasive techniques simultaneously to learn about the electromechanical properties of fasciculations.


Our most recent project focuses on the introduction of remote home SPiQE monitoring. We believe this approach will dramatically increase the accessibility of this technique, maximising our understanding of neuronal impairment in ALS.


The target number of patients for each are shown (MND=Motor Neuron Disease; BFS=Benign Fasciculation Syndrome).

  • MND
  • BFS
  • Healthy controls

Study progress

The proportion of target data collected for each study is highlighted below. However, even when all data have been collected, there can be a long period of time required for sufficient analysis and dissemination of results.

Please refer to our Publications and Blog pages for updates on our key results.

Core 100%
Daytime variability 100%
Ultrasound & EMG 100%
Remote pilot 0%

If you or someone you know would like to participate in any of our studies, please contact us at spiqe-info@kcl.ac.uk


A member of our team will be able to provide further details and assess eligibility